Assessing potential of psilocybin for depressive disorders
INTRODUCTION: There has been increasing interest in the role psilocybin may play in the treatment of depressive disorders. Several clinical trials have shown psilocybin to have efficacy in reducing symptoms of depression.
AREASCOVERED: We discuss the current understanding of psilocybin's therapeutic mechanism of action and review existing clinical data investigating psilocybin as a novel therapeutic agent for the treatment of depression.
EXPERT OPINION: There is still much unknown regarding the risks of psilocybin treatment. When weighing the known risks and benefits of psilocybin treatment against those found in existing standards of care, among patients with depression, patients with treatment-resistant depression (TRD) may be the most suitable candidates for psilocybin treatment at this time.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
Expert opinion on investigational drugs - 32(2023), 10 vom: 20. Juli, Seite 887-900 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kozak, Zofia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
2RV7212BP0 |
|---|
| Anmerkungen: |
Date Completed 07.11.2023 Date Revised 07.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/13543784.2023.2273493 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36362113X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36362113X | ||
| 003 | DE-627 | ||
| 005 | 20231226093737.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/13543784.2023.2273493 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1212.xml |
| 035 | |a (DE-627)NLM36362113X | ||
| 035 | |a (NLM)37869790 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kozak, Zofia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Assessing potential of psilocybin for depressive disorders |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.11.2023 | ||
| 500 | |a Date Revised 07.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: There has been increasing interest in the role psilocybin may play in the treatment of depressive disorders. Several clinical trials have shown psilocybin to have efficacy in reducing symptoms of depression | ||
| 520 | |a AREASCOVERED: We discuss the current understanding of psilocybin's therapeutic mechanism of action and review existing clinical data investigating psilocybin as a novel therapeutic agent for the treatment of depression | ||
| 520 | |a EXPERT OPINION: There is still much unknown regarding the risks of psilocybin treatment. When weighing the known risks and benefits of psilocybin treatment against those found in existing standards of care, among patients with depression, patients with treatment-resistant depression (TRD) may be the most suitable candidates for psilocybin treatment at this time | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Major depressive disorder | |
| 650 | 4 | |a depression in chronic illness | |
| 650 | 4 | |a psilocybin, psychedelics | |
| 650 | 4 | |a psychedelic-assisted therapy | |
| 650 | 4 | |a treatment-resistant depression | |
| 650 | 7 | |a Psilocybin |2 NLM | |
| 650 | 7 | |a 2RV7212BP0 |2 NLM | |
| 650 | 7 | |a Hallucinogens |2 NLM | |
| 700 | 1 | |a Johnson, Matthew W |e verfasserin |4 aut | |
| 700 | 1 | |a Aaronson, Scott T |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on investigational drugs |d 1995 |g 32(2023), 10 vom: 20. Juli, Seite 887-900 |w (DE-627)NLM093775326 |x 1744-7658 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2023 |g number:10 |g day:20 |g month:07 |g pages:887-900 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/13543784.2023.2273493 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2023 |e 10 |b 20 |c 07 |h 887-900 | ||